|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, over-expression of (V600E)BRAF increases migration and invasion of wild-type BRAF thyroid cells.
|
23435375 |
2013 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
In contrast, age- and size-matched classic papillary microcarcinomas (n=26) showed no extrathyroidal extension (p=0.002), lymphovascular invasion in 1, central compartment lymph node metastasis in 2, lateral cervical node metastasis in 1, multifocal tumors in 10 (38.5%), the BRAF(V600E) mutation in 20 (76.9%), and it infrequently presented in stage III/IVA (7.7%, p=0.02).
|
23682579 |
2013 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation status has been compared with well-known histopathological and clinical prognostic parameters such as invasion of thyroid capsule, extrathyroidal extension, and the presence of lymph node and/or distant metastasis.
|
22767446 |
2012 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, statistically significant correlations of BRAF(V600E) with indicators of tumor aggressiveness such as thyroid capsular invasion, multifocality, lymph node metastasis, and extrathyroidal spread were found.
|
22426956 |
2012 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
On univariate analysis, the BRAF(V600E) mutation was associated with extrathyroidal extension (P = .009) and variants of PTC (P = .019), but a high-risk Metastasis, Patient Age, Completeness of resection, local Invasion and Tumor Size (MACIS) score (≥ 6) (P = .146) and lymph node metastasis (P = .628) were not significantly associated with the BRAF(V600E) mutation.
|
21803329 |
2012 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
|
22105775 |
2012 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we have shown that PLX4720 preferentially inhibits migration and invasion of B-Raf(V600E) thyroid cancer cells and tumor aggressiveness.
|
21355020 |
2011 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with PTC harboring the BRAF(V600E) mutation seem to display a more aggressive clinical behavior, but little is known about the role of this mutation in crucial processes in the tumor microenvironment, such as tumor adhesion, migration, invasion, and metastasis.
|
21447745 |
2011 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.
|
20406109 |
2010 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis.
|
20498063 |
2010 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data indicate that BRAF(V600E) is associated some of the aggressive clinicopathological features of PTC including younger age at diagnosis, larger tumor size, and classic histological type, as well as also extrathyroidal invasion.
|
19355825 |
2009 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor size, extracapsular invasion, and high TNM stage (III and IV) were significantly associated with BRAF(V600E) in multivariate analysis.
|
19710001 |
2009 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002).
|
18682506 |
2008 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
The association between BRAF((V600E)) and extra-thyroid invasion</span> was also found in micro-PTCs (P=0.006).
|
18310287 |
2008 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
|
16960555 |
2007 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with extrathyroidal invasion (P < 0.0001), multicentricity (P = 0.0026), presence of nodal metastases (P = 0.0009), class III vs. classes I and II (P < 0.00000006), and absence of tumor capsule (P < 0.0001), in particular in follicular- and micro-PTC variants.
|
17785355 |
2007 |